Gallium-68/Copper-64-FAPI-XT117 - Sinotau pharmaceuticals
Alternative Names: 68Ga/64Cu-FAPI-XT117Latest Information Update: 05 Jan 2024
At a glance
- Originator Sinotau Pharmaceuticals
- Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 18 Dec 2023 Sinotau Pharmaceutical completes a phase I trial in Solid tumours (Diagnosis) in China (IV) (NCT05930457)
- 18 Dec 2023 Sinotau Pharmaceutical completes a phase I trials in Solid tumours (Diagnosis) in China (IV) (NCT05814835)
- 10 Jul 2023 Sinotau Pharmaceutical plans a phase I trial for Solid tumours(Diagnosis) (Parenteral, Injection) (NCT05930457)